8 May 2025

UKKA invites Expressions of Interest for national commentary

UK kidney professionals are invited to express interest in contributing to a commentary on the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Published online in January 2025, this landmark KDIGO guideline is the first dedicated to ADPKD - a complex inherited condition affecting up to 12 million people globally and the most common monogenic kidney disease leading to kidney failure. The guideline delivers up-to-date, evidence-based recommendations for the diagnosis, prognosis and management of ADPKD, covering areas such as imaging, genetic tools, extrarenal manifestations, reproductive health and disease-modifying treatments like tolvaptan.

KDIGO’s ADPKD guideline also introduces a new nomenclature and emphasises shared decision-making, individualised care, and approaches tailored to local healthcare systems - making national-level interpretation crucial. The UK Kidney Association (UKKA) will be developing a commentary that considers the guideline’s applicability in the UK context, including implications for NHS services, clinical pathways and multi-professional care teams.

Get involved
We are now seeking expressions of interest from healthcare professionals across the UK kidney community to contribute to this commentary. This includes those working in adult or paediatric nephrology, imaging, genetics, pharmacy, nursing, or any area of care affected by ADPKD.

To apply, please send a short statement (no more than 300 words) outlining:

  • Why you would like to be involved

  • Relevant expertise or experience

  • Whether you would be interested in a chairing role

Please also complete and attach a conflict of interest form and send both documents to ukka@ukkidney.org by 8 June 2025.

About the guideline
Co-chaired by Professor Olivier Devuyst (Switzerland) and Professor Vicente Torres (United States), the KDIGO ADPKD guideline was developed through a global collaborative effort. It applies the GRADE approach for grading the quality of evidence and includes practical tools and infographics to support implementation. It addresses the full spectrum of ADPKD care - from risk stratification using Mayo Imaging Classification and PROPKD scores, to managing complications, comorbidities, and reproductive considerations.

Learn more on the KDIGO website.